Phase 2 N=58 Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Primary: Plerixafor Maximum Tolerated Dose (MTD) [Phase I] — 320 ug/kg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=101 A Community Partnership to Treat Stroke
Stroke
Primary: Completion — 64 Participants
Phase 4 N=33 Modafinil for Treatment of Cognitive Dysfunction in Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Percent Change in Accuracy on High-control (i.e., Difficult) Condition of Preparing to Overcome Prepotency Task — 8.6; 9.2 percent change in accuracy
Phase 4 N=29 Modafinil Effects on Cognition in Schizophrenia Patients
Schizophrenia
Primary: Cognitive Performance — 76.7; 75.5; 67.2; 77.1 percentage correct of all trials
Phase 2 N=126 Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Proportion of Subjects Surviving at 1 Year — 29; 12 Participants
Phase 3 N=461 A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)
Type 2 Diabetes Mellitus
Primary: Change From Baseline In A1C at Week 26 — -0.79; -0.96; 0.20 Percent — p=<0.001
N/A N=98 A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment
Opiate Dependence
Primary: Percentage of Months in Methadone Treatment — 81; 82; 88 percent of months in methadone treatment — p=0.60
Phase 2 N=164 A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Symptom Scale (PANSS) Total Score at Week 6 — -14.08; -19.54 score on a scale — p=0.115
Phase 1 N=35 Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects
Healthy
Primary: AUC0-tz (Area Under the Concentration-time Curve of Free Dabigatran in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point) — 600; 714…
Phase 1 N=27 Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects
Kidney Failure, Chronic
Primary: Pharmacokinetic Parameter Cmax of Ticagrelor — 560.32; 598.35; 370.76 ng/mL
N/A N=29 Peer to Peer Delivery of Behavioral Activation
Depression
Primary: Proportion of Peer to Peer Coaches Who Undergo Behavioral Activation Training and Achieve Certification — 7 Participants
N/A N=16 Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study
Acute Asthma
Primary: %FEV1 — 20; 34; 26; 31 %-predicted
Phase 2 N=22 Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease
Sickle Cell Disease
Primary: Event -Free Survival Rate — 19 Participants
Phase 3 N=295 Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial
Cardiac Arrest
Primary: Survival With Good Neurobehavioral Outcome — 27; 15; 111; 107 Participants — p=0.14
Phase 2 N=50 Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration
Primary: Maximum Analyte Serum Concentration [Cmax (ng/mL)] — 20.7; 77.6 ng/mL